Stockscreener 앱 받기
172.51
0.79%
-1.37
시간 외 거래:
172.51
전일 마감가:
$173.88
열려 있는:
$171.73
하루 거래량:
899.60K
Relative Volume:
0.61
시가총액:
$10.95B
수익:
$763.34M
순이익/손실:
$51.40M
주가수익비율:
189.91
EPS:
0.9084
순현금흐름:
$104.46M
1주 성능:
-8.97%
1개월 성능:
+4.44%
6개월 성능:
+43.64%
1년 성능:
+18.78%
1일 변동 폭
$169.90
$173.82
1주일 범위
$157.44
$194.36
52주 변동 폭
$100.99
$198.87
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, RMD, MDLN, ALC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
172.51 | 10.95B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-09 | 재개 | UBS | Buy |
| 2026-07-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2026-06-02 | 재개 | Wolfe Research | Outperform |
| 2026-05-15 | 재개 | RBC Capital Mkts | Outperform |
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
RGEN5964422 Bond Profile: Coupon and Redemption - TradingView
Repligen Corp (BSP:R2GE34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is It Too Late to Buy Repligen Corp (RGEN) After 6.1% Rally? GF Value Says Undervalued - GuruFocus
Repligen Corp (RGEN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer. - Stock Titan
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. - Stock Titan
Repligen CEO Olivier Loeillot sells $1.03m of company stock By Investing.com - Investing.com Nigeria
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,535 Shares - GuruFocus
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tel - GuruFocus
Repligen CEO Olivier Loeillot sells $1.03m of company stock - Investing.com
Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan. - Stock Titan
Repligen Closes BioLife Solutions Acquisition - Yahoo Finance
Repligen completes acquisition of BioLife Solutions - Investing.com
18 commercially approved therapies are supported by BioLife's cell-preserving media. Repligen completed the deal. - stocktitan.net
Repligen Completes Acquisition of BioLife Solutions - Yahoo Finance
Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com South Africa
Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus
Loeillot proposes selling 4,202 Repligen (RGEN) shares through Fidelity. - stocktitan.net
For stock-grant taxes, Repligen (RGEN) withholds 1,248 CEO shares at $181.70 each. - stocktitan.net
Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com Nigeria
1,333 shares vested October 2 are proposed for sale at Repligen (NASDAQ: RGEN). - stocktitan.net
BioLife Solutions Shareholders Approve Repligen Merger Agreement - Yahoo Finance
REPLIGEN CORP. R (RGN.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada
Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada
A Look at Repligen Corp (RGEN) After 7.8% Decline -- GF Value $1 - GuruFocus
Continuous Bioprocessing Technologies MarketGlobal Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR - GlobeNewswire Inc.
Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com South Africa
Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com UK
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingView
After a stock-unit release, Repligen (RGEN) withheld 421 shares from its CFO to cover taxes. - Stock Titan
Repligen CEO Olivier Loeillot sells $976,680 in company stock - Investing.com
Repligen CEO Loeillot sells $2.46m in shares - Investing.com
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus
Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan
Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria
Repligen Corporation (RGEN) Stock Forecasts - finance.yahoo.com
Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus
Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan
Repligen Corp Stock Baskets - GuruFocus
Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus
Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com
Repligen Corporation stock hits 52-week high at 188.95 USD By Investing.com - Investing.com UK
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Repligen Corp 주식 (RGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Officer |
Oct 05 '26 |
Proposed Sale |
190.00 |
4,202 |
798,380 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Oct 05 '26 |
Sale |
187.29 |
5,535 |
1,036,654 |
45,788 |
| Loeillot Olivier | Officer |
Oct 05 '26 |
Proposed Sale |
178.75 |
1,333 |
238,274 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Sale |
190.00 |
12,946 |
2,459,740 |
48,369 |
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Option Exercise |
155.11 |
12,946 |
2,008,020 |
56,773 |
| Loeillot Olivier | Officer |
Sep 24 '26 |
Proposed Sale |
190.00 |
12,946 |
2,459,740 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 21 '26 |
Sale |
180.00 |
5,426 |
976,680 |
48,369 |
| Loeillot Olivier | Chief Executive Officer |
Sep 21 '26 |
Option Exercise |
141.79 |
5,426 |
769,353 |
53,795 |
| Loeillot Olivier | Officer |
Sep 21 '26 |
Proposed Sale |
180.00 |
5,426 |
976,680 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 04 '26 |
Sale |
165.90 |
3,035 |
503,506 |
48,369 |
2.16%
1.15%
자본화:
|
볼륨(24시간):